Drug Type Fusion protein |
Synonyms KNP 301, KNP-301 |
Target |
Mechanism C3 inhibitors(Complement C3 inhibitors), VEGF modulators(Vascular endothelial growth factor modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization KANAPH Therapeutics, Inc.Startup |
Active Organization KANAPH Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Neuropathies | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 30 Jan 2022 |
Diabetic macular oedema | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 21 Nov 2020 |
dry age-related macular degeneration | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 21 Nov 2020 |
Wet age-related macular degeneration | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 21 Nov 2020 |
Wet Macular Degeneration | Preclinical | KR | - | - |